IMGN News and Press, ImmunoGen Inc. From 02/11/21

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upco...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 12, 2021 to discuss its 2020 operating results. Management ...

ImmunoGen (IMGN) expects to report ~$294M of cash and cash equivalents for the year ended December 31, 2020.Dive deeper into the company presentation. For further details see: ImmunoGen provides Q4 guidance

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 39 th Annual J.P. Morgan Virtual Healthcare Conference. The presentati...

After ImmunoGen shares were decimated, the company learned from its mistakes. And, they're now embarking on a path toward a spectacular turnaround. The lead medicine, Mirve, is progressing in two Phase 3 trials with a data release as early as next year. Meanwhile, other pipeline m...

Updated Data Demonstrating Favorable Safety Profile and Encouraging Monotherapy Activity in BPDCN Presented During Oral Session Preclinical Combination Data in Relapsed/Refractory AML Support Further Evaluation of Triplet; Trial in Progress Poster for Phase 1b/2 Study Presente...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00am ET on Monday, December 7, 2020 to discuss updated findings from the first-in-human tr...

ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: Piper Sandler 32 nd ...

ImmunoGen, Inc. (IMGN) Q3 2020 Earnings Conference Call November 06, 2020, 08:00 AM ET Company Participants Courtney O'Konek - Senior Director, Corporate Communications and IR Mark Enyedy - President and CEO Susan Altschuller - CFO Anna Berkenblit - Chief Medical Officer Conference Call Parti...

Image source: The Motley Fool. Immunogen Inc (NASDAQ: IMGN) Q3 2020 Earnings Call Nov 6, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Immunogen Inc (IMGN) Q3 2020 Earnings Call Transcript